Tejas Savant
Stock Analyst at Morgan Stanley
(2.19)
# 2,700
Out of 4,732 analysts
217
Total ratings
39.53%
Success rate
-4.37%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher | Maintains: Overweight | $670 → $647 | $559.65 | +15.61% | 13 | Jan 13, 2025 | |
| ILMN Illumina | Maintains: Equal-Weight | $156 → $150 | $136.67 | +9.75% | 6 | Jan 13, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $84 → $82 | $69.73 | +17.60% | 8 | Jan 13, 2025 | |
| TXG 10x Genomics | Maintains: Overweight | $30 → $28 | $15.08 | +85.68% | 12 | Jan 13, 2025 | |
| STVN Stevanato Group | Assumes: Equal-Weight | $24 → $23 | $22.85 | +0.66% | 1 | Dec 3, 2024 | |
| GRAL GRAIL | Initiates: Equal-Weight | $16 | $17.42 | -8.15% | 1 | Nov 27, 2024 | |
| VCYT Veracyte | Maintains: Underweight | $26 → $28 | $40.58 | -31.00% | 13 | Nov 18, 2024 | |
| MYGN Myriad Genetics | Maintains: Equal-Weight | $32 → $21 | $12.39 | +69.49% | 2 | Nov 18, 2024 | |
| NTRA Natera | Maintains: Overweight | $132 → $176 | $158.36 | +11.14% | 12 | Nov 14, 2024 | |
| IQV IQVIA Holdings | Maintains: Overweight | $280 → $265 | $197.36 | +34.27% | 10 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $11 → $10 | $4.77 | +109.64% | 12 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.64 | +21.95% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $3 | $2.82 | +6.38% | 10 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $29 | $22.11 | +31.16% | 15 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $35.15 | +25.18% | 1 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $10.83 | +269.34% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $5.46 | +28.21% | 8 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $14.21 | +19.63% | 12 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $10 | $6.81 | +46.84% | 11 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $16 | $7.50 | +113.33% | 1 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $1.93 | +210.88% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $3.12 | +220.51% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $1.23 | +123.58% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $4.89 | +2.25% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.29 | +336.68% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $36.66 | +99.13% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $163.50 | +52.91% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $1.15 | +334.78% | 5 | May 12, 2022 |
Thermo Fisher
Jan 13, 2025
Maintains: Overweight
Price Target: $670 → $647
Current: $559.65
Upside: +15.61%
Illumina
Jan 13, 2025
Maintains: Equal-Weight
Price Target: $156 → $150
Current: $136.67
Upside: +9.75%
Hologic
Jan 13, 2025
Maintains: Equal-Weight
Price Target: $84 → $82
Current: $69.73
Upside: +17.60%
10x Genomics
Jan 13, 2025
Maintains: Overweight
Price Target: $30 → $28
Current: $15.08
Upside: +85.68%
Stevanato Group
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $22.85
Upside: +0.66%
GRAIL
Nov 27, 2024
Initiates: Equal-Weight
Price Target: $16
Current: $17.42
Upside: -8.15%
Veracyte
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $40.58
Upside: -31.00%
Myriad Genetics
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $12.39
Upside: +69.49%
Natera
Nov 14, 2024
Maintains: Overweight
Price Target: $132 → $176
Current: $158.36
Upside: +11.14%
IQVIA Holdings
Nov 4, 2024
Maintains: Overweight
Price Target: $280 → $265
Current: $197.36
Upside: +34.27%
Aug 13, 2024
Downgrades: Equal-Weight
Price Target: $11 → $10
Current: $4.77
Upside: +109.64%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.64
Upside: +21.95%
Aug 6, 2024
Downgrades: Equal-Weight
Price Target: $4 → $3
Current: $2.82
Upside: +6.38%
Jul 29, 2024
Maintains: Overweight
Price Target: $28 → $29
Current: $22.11
Upside: +31.16%
Jul 9, 2024
Initiates: Overweight
Price Target: $44
Current: $35.15
Upside: +25.18%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $10.83
Upside: +269.34%
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $5.46
Upside: +28.21%
Nov 8, 2023
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $14.21
Upside: +19.63%
Oct 24, 2023
Maintains: Equal-Weight
Price Target: $13 → $10
Current: $6.81
Upside: +46.84%
Aug 17, 2023
Initiates: Equal-Weight
Price Target: $16
Current: $7.50
Upside: +113.33%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $1.93
Upside: +210.88%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $3.12
Upside: +220.51%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $1.23
Upside: +123.58%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $4.89
Upside: +2.25%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.29
Upside: +336.68%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $36.66
Upside: +99.13%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $163.50
Upside: +52.91%
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.15
Upside: +334.78%